Suchergebnisse - "Chihara, Yusuke"

PubPharm (102)

1

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis : Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

enthalten in: Targeted oncology | 2024

von Nishioka, N. | Imai, H. | Endo, M. | +35

2

Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors : the Tokushukai REAl-world Data project 01-S1

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Uryu, K. | Imamura, Y. | Shimoyama, R. | +19

3

Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC : A Prospective Study

enthalten in: JTO clinical and research reports | 2024

von Katayama, Y. | Yamada, T. | Morimoto, K. | +17

4

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer : Focus on Older Patients

enthalten in: Targeted oncology | 2024

von Onoi, K. | Yamada, T. | Morimoto, K. | +14

5

Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer : the Tokushukai REAl-world Data project (TREAD 01)

enthalten in: Japanese journal of clinical oncology | 2024

von Uryu, K. | Imamura, Y. | Shimoyama, R. | +18

6

Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer

enthalten in: The oncologist | 2024

von Katayama, Y. | Yamada, T. | Sawada, R. | +13

7

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50

enthalten in: Frontiers in immunology | 2024

von Takei, S. | Kawachi, H. | Yamada, T. | +20

8

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49% : a multicenter retrospective study

enthalten in: Frontiers in oncology | 2024

von Yoshimura, A. | Takeda, T. | Kataoka, N. | +18

9

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression : Focus on the Role of Performance Status

enthalten in: Targeted oncology | 2023

von Morimoto, K. | Yamada, T. | Kawachi, H. | +19

10

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status

enthalten in: Targeted oncology | 2023

von Morimoto, K. | Yamada, T. | Kawachi, H. | +19

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]